Understanding human NK cell differentiation: Clues for improving the haploidentical hematopoietic stem cell transplantation

Immunology Letters

Volumn 155, Issue 1-2, 2013, Pages 2-5

  Montaldo, Elisa ^a   Vacca, Paola ^a   Moretta, Lorenzo ^b   Mingari, Maria Cristina ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Allogeneic HSC transplantation; NK cell differentiation; NK cells; NK receptors

Indexed keywords

CD33 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 8; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ALLOIMMUNITY; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; CELL POPULATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ALLOGENEIC HSC TRANSPLANTATION; NK CELL DIFFERENTIATION; NK CELLS; NK RECEPTORS;

ANIMALS; CELL DIFFERENTIATION; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; LYMPHOID PROGENITOR CELLS; QUALITY IMPROVEMENT;

EID: 84887822968     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.09.022     Document Type: Review

References (58)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47:187-376.
2. Lanier L.L., Chang C., Azuma M., Ruitenberg J.J., Hemperly J.J., Phillips J.H. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol 1991, 146:4421-4426.
3. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
4. + NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA 2011, 108:728-732.
5. Fauriat C., Long E.O., Ljunggren H.G., Bryceson Y.T. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010, 115:2167-2176.
6. Karre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
7. + natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990, 172:1589-1598.
8. + natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med 1990, 171:695-714.
9. Moretta A., Vitale M., Bottino C., Orengo A.M., Morelli L., Augugliaro R., et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 1993, 178:597-604.
10. Wagtmann N., Biassoni R., Cantoni C., Verdiani S., Malnati M.S., Vitale M., et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 1995, 2:439-449.
11. Ciccone E., Pende D., Viale O., Than A., Di Donato C., Orengo A.M., et al. Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2). J Exp Med 1992, 176:963-971.
12. Vitale M., Sivori S., Pende D., Moretta L., Moretta A. Coexpression of two functionally independent p58 inhibitory receptors in human natural killer cell clones results in the inability to kill all normal allogeneic target cells. Proc Natl Acad Sci USA 1995, 92:3536-3540.
13. Pende D., Biassoni R., Cantoni C., Verdiani S., Falco M., di Donato C., et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med 1996, 184:505-518.
14. Moretta A., Sivori S., Vitale M., Pende D., Morelli L., Augugliaro R., et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995, 182:875-884.
15. Lopez-Botet M., Perez-Villar J.J., Carretero M., Rodriguez A., Melero I., Bellon T., et al. Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. Immunol Rev 1997, 155:165-174.
16. Braud V.M., Allan D.S., O'Callaghan C.A., Soderstrom K., D'Andrea A., Ogg G.S., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799.
17. Sivori S., Vitale M., Morelli L., Sanseverino L., Augugliaro R., Bottino C., et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997, 186:1129-1136.
18. Pessino A., Sivori S., Bottino C., Malaspina A., Morelli L., Moretta L., et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998, 188:953-960.
19. Vitale M., Bottino C., Sivori S., Sanseverino L., Castriconi R., Marcenaro E., et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998, 187:2065-2072.
20. Cantoni C., Bottino C., Vitale M., Pessino A., Augugliaro R., Malaspina A., et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999, 189:787-796.
21. Pende D., Parolini S., Pessino A., Sivori S., Augugliaro R., Morelli L., et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999, 190:1505-1516.
22. Moretta A., Biassoni R., Bottino C., Mingari M.C., Moretta L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 2000, 21:228-234.
23. Moretta L., Biassoni R., Bottino C., Mingari M.C., Moretta A. Human NK-cell receptors. Immunol Today 2000, 21:420-422.
24. Brandt C.S., Baratin M., Yi E.C., Kennedy J., Gao Z., Fox B., et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009, 206:1495-1503.
25. Pogge von Strandmann E., Simhadri V.R., von Tresckow B., Sasse S., Reiners K.S., Hansen H.P., et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007, 27:965-974.
26. Arnon T.I., Achdout H., Levi O., Markel G., Saleh N., Katz G., et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005, 6:515-523.
27. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
28. Bottino C., Castriconi R., Pende D., Rivera P., Nanni M., Carnemolla B., et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003, 198:557-567.
29. Shi F.D., Ljunggren H.G., La Cava A., Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol 2011, 11:658-671.
30. Moroso V., Famili F., Papazian N., Cupedo T., van der Laan L.J., Kazemier G., et al. NK cells can generate from precursors in the adult human liver. Eur J Immunol 2011, 41:3340-3350.
31. + hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci USA 2011, 108:2402-2407.
32. Chinen H., Matsuoka K., Sato T., Kamada N., Okamoto S., Hisamatsu T., et al. Lamina propria c-kit+immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 2007, 133:559-573.
33. Chiossone L., Chaix J., Fuseri N., Roth C., Vivier E., Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood 2009, 113:5488-5496.
34. Freud A.G., Caligiuri M.A. Human natural killer cell development. Immunol Rev 2006, 214:56-72.
35. Blom B., Spits H. Development of human lymphoid cells. Annu Rev Immunol 2006, 24:287-320.
36. Perez S.A., Sotiropoulou P.A., Gkika D.G., Mahaira L.G., Niarchos D.K., Gritzapis A.D., et al. A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood 2003, 101:3444-3450.
37. + cord blood precursors toward NK cells. Int Immunol 2008, 20:565-575.
38. Grzywacz B., Kataria N., Blazar B.R., Miller J.S., Verneris M.R. Natural killer-cell differentiation by myeloid progenitors. Blood 2011, 117:3548-3558.
39. + RORgammat+ innate lymphoid cells and conventional natural killer cells. Blood 2013, 121:2234-2243.
40. Gascoyne D.M., Long E., Veiga-Fernandes H., de Boer J., Williams O., Seddon B., et al. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 2009, 10:1118-1124.
41. Aliahmad P., de la Torre B., Kaye J. Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat Immunol 2010, 11:945-952.
42. Yun S., Lee S.H., Yoon S.R., Kim M.S., Piao Z.H., Myung P.K., et al. TOX regulates the differentiation of human natural killer cells from hematopoietic stem cells in vitro. Immunol Lett 2011, 136:29-36.
43. Freud A.G., Yokohama A., Becknell B., Lee M.T., Mao H.C., Ferketich A.K., et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006, 203:1033-1043.
44. Huntington N.D., Legrand N., Alves N.L., Jaron B., Weijer K., Plet A., et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009, 206:25-34.
45. Juelke K., Killig M., Luetke-Eversloh M., Parente E., Gruen J., Morandi B., et al. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 2010, 116:1299-1307.
46. Chan A., Hong D.L., Atzberger A., Kollnberger S., Filer A.D., Buckley C.D., et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 2007, 179:89-94.
47. Spits H., Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 2012, 30:647-675.
48. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013, 13:145-149.
49. Montaldo E., Vitale C., Cottalasso F., Conte R., Glatzer T., Ambrosini P., et al. Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor. Blood 2012, 119:3987-3996.
50. Montaldo E., Del Zotto G., Della Chiesa M., Mingari M.C., Moretta A., De Maria A., et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry Part A, J Int Soc Anal Cytol 2013.
51. Sivori S., Falco M., Marcenaro E., Parolini S., Biassoni R., Bottino C., et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci USA 2002, 99:4526-4531.
52. Pende D., Marcenaro S., Falco M., Martini S., Bernardo M.E., Montagna D., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113:3119-3129.
53. + cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol 2003, 33:3439-3447.
54. Moretta A., Pende D., Locatelli F., Moretta L. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias. Clin Exp Immunol 2009, 157:325-331.
55. Moretta L., Locatelli F., Pende D., Marcenaro E., Mingari M.C., Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011, 117:764-771.
56. Karre K. Immunology. A perfect mismatch. Science 2002, 295:2029-2031.
57. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
58. Della Chiesa M., Falco M., Podesta M., Locatelli F., Moretta L., Frassoni F., et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood 2012, 119:399-410.